Optimizing First-Line Therapeutics in Non-Small Cell Lung Cancer: Insights from Joint Modeling and Large-Scale Data Analysis

Abstract

Insights from Joint Modeling and Large-Scale Data Analysis Authors: ['Benjamin Schneider' 'Sébastien Benzekry' 'Jonathan P. Mochel'] - Non-small cell lung cancer (NSCLC) is a leading cause of mortality. Many treatments for NSCLC rely on combination therapy with bevacizumab, an anti-VEGF adjunct. - Evidence is presented that scheduling bevacizumab several hours before combination antiproliferatives improves treatment efficacy, via a mathematical model built using patient data collated from 11 clinical trials in NSCLC. - This work indicates that future trials in NSCLC with bevacizumab should test staggered sequential scheduling. Furthermore, a model fit on a large human clinical trial dataset is provided for future modeling and simulation work in NSCLC.